Search
Hexokinase-1
go.drugbank.com/bio_entities/BE0001108TargetEnzymeHumansInvolved in innate immunity and inflammation by acting as a pattern recognition receptor for bacterial peptidoglycan (PubMed:27374331). … Mediates the initial step of glycolysis by catalyzing phosphorylation of D-glucose to D-glucose 6-phosphate (By similarity).
Synonyms: Brain form hexokinaseNV-52
go.drugbank.com/drugs/DB05673ExperimentalNV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.
Diacetyl benzoyl lathyrol
go.drugbank.com/drugs/DB11260ApprovedIt is also reported to be a skin conditioning agent.
Mixtures: O HUI white-skin science white calming maskPlozalizumab
go.drugbank.com/drugs/DB12520InvestigationalPlozalizumab has been investigated for the treatment of Atherosclerosis. … The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis.
Dasotraline
go.drugbank.com/drugs/DB12305InvestigationalDasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention
Ibrigampar
go.drugbank.com/drugs/DB05490InvestigationalAMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. … T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin.
AK119
go.drugbank.com/drugs/DB16423InvestigationalAK119 is a humanized anti-CD73 monoclonal antibody being investigated in the clinical trial NCT04516564 (A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects).[L28315]
Vicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. … This drug was developed by Schering-Plough.
Prenylamine
go.drugbank.com/drugs/DB04825ApprovedWithdrawnPrenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.